Analysis of the Impact of Used Probiotic Strains and Diet on Body Composition, Cardiopulmonary Efficiency and the Incidence of Gastrointestinal Disorders in Runners

August 25, 2020 updated by: Medical University of Bialystok

The aim of the study was to assess the diet and the effect of probiotic therapy on reducing the incidence of gastrointestinal disorders and selected parameters determining the inflammation of the body, body composition, cardiopulmonary efficiency and selected serum biochemical parameters.

70 competitors took part in the study. The research was carried out at the Department of Dietetics and Clinical Nutrition (Medical University of Bialystok), Fitness Club Maniac Gym in Bialystok, as well as at the Hematological Diagnostics Department and the Biochemical Diagnostics Department of the University Teaching Hospital in Bialystok.

The study was randomized using a double-blind trial. 35 persons selected in the draw were G1 group and the remaining G2 group (n=35). The intervention factor was the SANPROBI BARRIER multi-strain probiotic or placebo. Competitors used probiotic/ placebo for three months at a dose of 2x2 capsules daily (2.5 x 10 9 CFU / g (1 capsule)). The consent of the Bioethics Committee of the Medical University, no. RI-002/81/2017, was obtained for the study.

The study consisted of two stages (W1 and W2), and each stage was associated with three visits by the participants. The first of these (W1) included qualification for the study, completing the questionnaire and 3-day nutrition diaries. At the second visit, body composition analysis and cardiopulmonary efficiency test on a medical treadmill were performed. For morphological tests (blood count with smear, lipid profile, fasting glucose, C-reactive protein and ionogram) at the third visit for each competitor was collected blood from the vein in the amount of 10 ml. The final stage (W2) included similar three visits, where the first visit was made after 3 months of taking product A or B. 66 competitors took part in it.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

The aim of the study was to assess the diet and the effect of probiotic therapy on reducing the incidence of gastrointestinal disorders and selected parameters determining the inflammation of the body, body composition, cardiopulmonary efficiency and selected serum biochemical parameters.

The approved of the Bioethics Committee of the Medical University, no. RI-002/81/2017, was obtained for the study. 70 people meeting the inclusion criteria were included in the intervention and observational study. The research was carried out at the Department of Dietetics and Clinical Nutrition at the Faculty of Health Sciences of the Medical University of Bialystok, Fitness Club Maniac Gym in Bialystok, as well as at the Hematological Diagnostics Department and the Biochemical Diagnostics Department of the University Clinical Hospital in Bialystok.

The study took place in the spring (March-June 2018) and autumn (September-December 2018), i.e. during of the most intense period in terms of participation in runners' competitions. The study was randomized using a double-blind trial. 35 persons selected in the draw were G1 group and the remaining G2 group (n=35). The tests were completely anonymous, the competitors gave their informed written consent to carry them out.

Interventional study was conducted using a probiotic or placebo. The observation period lasted three months. The intervention factor was the SANPROBI BARRIER multi-strain probiotic (commonly available in pharmacies) or placebo (created on the model of a probiotic capsule, specially for the needs of research, by Sanprobi Sp. z o.o.). Competitors used probiotic/ placebo for three months at a dose of 2x2 capsules daily (2.5 x 10 9 CFU / g (1 capsule)). The probiotic used in the study contained bacterial strains, i.e. Bifidobacterium lactis W52, Lactobacillus brevis W63, Lactobacillus casei W56, Lactococcus lactis W19, Lactococcus lactis W58, Lactobacillus acidophilus W37, Bifidobacterium bifidum W23, Lactobacillus salivarius W24. Players and researchers were not informed about the type of capsule taken (probiotic or placebo). Competitors were asked to use product A or B after blood tests.

Each player had 3 visits during the preliminary stage (W1) and 3 visits of the final stage (W2).

Preliminary stage (W1)

  1. The first visit took place in the Department of Dietetics and Clinical Nutrition at the Medical University of Bialystok. It included qualification for the study based on the criteria for inclusion in the study group, discussion of the purpose of the study and signing the written consent for the study by the participants, as well as information about the protection of their personal data and full anonymity. Each participant received an individual code (e.g. A01, A02, B01, B02 etc.), which was used to identify the subject in further stages. Athletes were asked not to use other probiotic strains than those used in the study. All competitors completed a survey regarding demographic data, information on dietary supplementation used, the incidence of gastrointestinal disorders, and 3-day nutrition diary.
  2. The second visit took place after a week. Each player was invited to the Maniac Gym Fitness Club in Bialystok. Body composition analysis was performed using an InBody 770 analyzer (InBody, Korea). To determine the level of cardiopulmonary efficiency using the Bruce protocol test on a medical treadmill were performed. Then, competitors were issued a referral for laboratory tests. During this meeting, in accordance with the simple draw product A (group G1) was given to every second person, and product B (group G2) for the remaining persons.
  3. For morphological tests (blood count with smear, lipid profile, fasting glucose, C-reactive protein and ionogram) at the third visit for each competitor was collected blood from the vein in the amount of 10 ml.

Final stage (W2) The final stage consisted of three visits (similar to the preliminary stage). The first visit was made after 3 months of taking product A or B by the competitors. 66 people took part in the final stage of the study (G1 = 34 people, G2 = 32 people). One person from group G1 (product A) did not report for the final visit without providing a specific reason. Three people from the G2 control group (product B) did not participate in the final stage of the study (W2) due to injury (2 people) and without providing a specific reason (1 person).

  • The first visit took place at the Department of Dietetics and Clinical Nutrition (Medical University of Bialystok) where competitors were completed the questionnaires to determine the changes in the incidence of gastrointestinal disorders.
  • The second visit was conducted at the Fitness Club Maniac Gym, where the cardiopulmonary fitness test and body composition analysis were carried out.

  • Third visit took place at the Hematological Diagnostics Department of the University Teaching Hospital in Bialystok, where from each participant the blood was collected (from the vein) in an amount of 10 ml for biochemical tests (as during the initial stage at visit 3).

    3-day nutrition diary: Each participant described customary meals consumed for the next three days, including two working days and one day off. The food diary includes hours of meals, the weight of products and dishes, and the amount of fluids consumed during the day. The competitors were asked to use the standard, current diet, without any significant changes. The energy value of the daily nutritional plan, the content of the main nutrients, vitamins, minerals, cholesterol and dietary fiber were taken into account in the evaluation of the three-day nutrition diary. Then, the percentage of compliance with the norm for the energy supply of diet and nutrients was assessed by comparing the results to Polish norms for healthy, adult men and women, and based on scientific research on the discipline of long-distance running.

Body composition analysis All competitors underwent body composition analysis using the InBody model 770 analyzer (South Korea). The body composition analyzer, using the electrical bioimpedance principle, uses low current flow using 6 frequencies and subsequent measurement of the resistance of individual tissues to determine body composition. The following parameters were assessed: body weight (kg), body fat content in kilograms and percent, visceral fat content (cm2), skeletal muscle mass (kg), body water content (kg). Before the test, the participants were informed about the need to stay fasting 8-12 hours and a minimum of 24 hours after physical activity. They were asked to avoid drinking liquids 1 h before the test. None of the competitors had an implanted pacemaker, which is an absolute exclusion criterion in the study of body composition analysis by electrical bioimpedance.

Analysis of cardiopulmonary efficiency In order to determine the cardiopulmonary efficiency of competitors, the Fitmate MED device (Cosmed, Italy) was used, which comprehensively determined cardiopulmonary efficiency and a medical treadmill adapted to this type of HpCosmos analysis (Germany). The Fitmate MED device is equipped with a sensor that enables the measurement of inhaled and exhaled air as well as a mask containing disposable mouthpieces and antibacterial filters. To monitor cardiac contractions, a Garmin sporttester model HRM-Tri 010-10997-09 (United States) was used. In cardiopulmonary fitness tests, a walking treadmill test was used according to Bruce's protocol. The exercise test included effort progression to increase walking speed and incline of the treadmill. The study was divided into 5 stages (3 minutes each). In the first of them, the walk took place at a speed of 2.7 km/h and a 10% incline of the treadmill. In the second stage, the treadmill accelerated to 4 km/h, and the incline increased to 12%. The third stage is a speed of 5.5 km / h and a incline 14%. The fourth stage is the speed increase to 6.8 km / h and the treadmill inclination 16%, and the last stage 5 is the speed of 8 km / h and the inclination of the treadmill 18%. Participants were informed that the cardiorespiratory fitness test should take place for a minimum of 2 weeks after intense physical effort (marathon, ultramarathon). During the test, the maximum test procedure was used to obtain more test parameters, and the test condition was considered to be 90% HRmax by the test subject, or the test could not be continued by interrupting it at the test subject's request. None of the competitors tested completed the test alone, they all reached the 90% HR max limit.

Laboratory tests The tests were performed after venous blood collection (from a vein in the arm) in the amount of 10 ml. Twice (during the initial and final stages) the following measurements were taken: complete blood count with smear, fasting glucose, total cholesterol, HDL, LDL and triglycerides, sodium, iron, potassium, magnesium, serum calcium, determination C-reactive protein (CRP) concentrations. In order to determine pro-inflammatory cytokines, blood was collected on a clot, it was subjected to centrifugation, and after clot separation, the obtained serum was stored at -80 degrees Celsius (until the tests were performed). To determine the concentration of interleukin 6 (IL-6) and tumor necrosis factor (TNF-alpha), the ELISA method (enzyme-linked immunosorbent assay) was used, using R&D System kits (Bio-Techne, United States) according to the manufacturer's instructions.

Study Type

Interventional

Enrollment (Actual)

66

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Poland
      • Białystok, Poland, 15-089
        • Medical University of Bialystok

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 58 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • women and men aged 20-60,
  • running trainings over 5 km/day

Exclusion Criteria:

  • use (other than in research) probiotics
  • pacemaker

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Group PROBIOTIC
The intervention factor was the SANPROBI BARRIER multi-strain probiotic (commonly available in pharmacies). Competitors used probiotic for three months at a dose of 2x2 capsules daily (2.5 x 109 CFU / g (1 capsule)).
Dietary supplement: SANPROBI BARRIER
Competitors used probiotic for three months at a dose of 2x2 capsules daily (2.5 x 109 CFU / g (1 capsule)).
Placebo Comparator: Group PLACEBO
Placebo created on the model of a probiotic capsule, specially for the needs of research, by Sanprobi Sp. z o.o.. Competitors used placebo for three months at a dose of 2x2 capsules daily.
Dietary supplement: PLACEBO
Competitors used placebo for three months at a dose of 2x2 capsules daily.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Influence of probiotic Sanprobi Barrier on the occurrence of gastrointestinal disorders of long-distance runners.
Time Frame: 12 weeks (assessment at baseline and after 3 months of probiotic / placebo use)

Subjective assessment (survey) of changes in the incidence and severity of gastrointestinal disorders in group of long-distance runners.

Another survey at the beginning and end of the study.
12 weeks (assessment at baseline and after 3 months of probiotic / placebo use)
Influence of probiotic Sanprobi Barrier on the body composition of long-distance runners.
Time Frame: 12 weeks (assessment at baseline and after 3 months of probiotic / placebo use)

Assessment of runner's body composition changes (body composition analysis used InBody 770 body composition analyzer).

The following parameters were assessed: body weight (kg), body fat content in kilograms and percent, visceral fat content (cm2), skeletal muscle mass (kg), body water content (kg).
12 weeks (assessment at baseline and after 3 months of probiotic / placebo use)
Influence of probiotic Sanprobi Barrier on the cardiopulmonary efficiency of long-distance runners.
Time Frame: 12 weeks (assessment at baseline and after 3 months of probiotic / placebo use)
Assessment of changes in cardiopulmonary efficiency of long-distance runners (testing the player's efficiency on a medical treadmill with the use of a sport tester and an oxygen mask. Bruce Test Protocol).
12 weeks (assessment at baseline and after 3 months of probiotic / placebo use)
Influence of probiotic Sanprobi Barrier on general inflammation of the body.
Time Frame: 12 weeks (assessment at baseline and after 3 months of probiotic / placebo use)
Assessment of changes in parameters (C-reactive protein, TNF-alpha, IL-6) from blood.
12 weeks (assessment at baseline and after 3 months of probiotic / placebo use)
Influence of probiotic Sanprobi Barrier on blood biochemical parameters.
Time Frame: 12 weeks (assessment at baseline and after 3 months of probiotic / placebo use)
Assessment of changes in parameters (complete blood count with smear, fasting glucose, total cholesterol, HDL, LDL and triglycerides, sodium, iron, potassium, magnesium, serum calcium) from blood.
12 weeks (assessment at baseline and after 3 months of probiotic / placebo use)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Medical University of Bialystok

Collaborators

Maniac Gym Bialystok
University Teaching Hospital, Bialystok

Investigators

  • Principal Investigator: Joanna Smarkusz-Zarzecka, PhD, Department of Dietetics and Clinical Nutrition, Medical University of Bialystok

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 1, 2018

Primary Completion (Actual)

December 31, 2018

Study Completion (Actual)

December 31, 2018

Study Registration Dates

First Submitted

August 10, 2020

First Submitted That Met QC Criteria

August 25, 2020

First Posted (Actual)

August 28, 2020

Study Record Updates

Last Update Posted (Actual)

August 28, 2020

Last Update Submitted That Met QC Criteria

August 25, 2020

Last Verified

August 1, 2020

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • N/ST/MN/18/003/3316

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Gastrointestinal Disorder, Functional

Clinical Trials on SANPROBI BARRIER

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Spain

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe